Collectively, these findings indicate DUOX1 silencing in lung cancer cells impacts on EGFR internalization and nuclear translocation in response to EGF, with corresponding consequences for EGFR-mediated cell proliferation and migration, as well as sensitivity to (antibody-based) EGFR targeting. The gene discussed is DUOX1; the disease is lung carcinoma.